Health Care & Life Sciences » Pharmaceuticals | Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc.
Stock Exchange NASDAQ Stock Market
EPS
$1.52
Market Cap
$190.63 M
Shares Outstanding
29.33 M
Public Float
19.6 M

Profile

Address
863 Mitten Road
Burlingame California 94010
United States
Employees -
Website http://www.corvuspharma.com
Updated 07/08/2019
Corvus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of small molecule and antibody agents that target crucial enzymes and proteins in the immune system to treat patients with cancer. Its product pipeline includes Adenosine A2A Receptor Antagonist CPI-444, Adenosine Production Inhibitor Anti-CD73, Adenosine A2B Receptor Antagonist, ITK Inhibitor, and Myeloid Cell Suppression. The company was founded by Richard A.

Financials

View All

Richard A. Miller
Chairman, President & Chief Executive Officer
Ian T. Clark
Independent Director